MicroMed DeBakey Trial Ready To Begin Following CMS Payment Change
This article was originally published in The Gray Sheet
Executive Summary
CMS' decision to reimburse axial flow left-ventricular assist devices at the same rate as positive displacement LVADs resulted from meetings between the agency and system developers and researchers, MicroMed says
You may also be interested in...
MicroMed DeBakey Heart-Assist Device Pivotal Trial Gets IDE Clearance
The pivotal study for MicroMed's DeBakey left-ventricular assist device will be led by Columbia University's Eric Rose, MD, the researcher who helped secure the first FDA approval and Medicare reimbursement of permanent LVADs
MicroMed DeBakey Heart-Assist Device Pivotal Trial Gets IDE Clearance
The pivotal study for MicroMed's DeBakey left-ventricular assist device will be led by Columbia University's Eric Rose, MD, the researcher who helped secure the first FDA approval and Medicare reimbursement of permanent LVADs
Clash Of The LVADs: Continuous Flow Devices Moved To Lower-Paying DRG
MicroMed is seeking to regain sufficient inpatient reimbursement for its DeBakey left-ventricular assist device by the time Medicare coverage for LVADs as destination therapy becomes effective